Literature DB >> 34364883

IFN-κ Is a Rheostat for Development of Psoriasiform Inflammation.

Mehrnaz Gharaee-Kermani1, Shannon N Estadt2, Lam C Tsoi3, Sonya J Wolf-Fortune2, Jianhua Liu4, Xianying Xing5, Jonathon Theros4, Tamra J Reed4, Lori Lowe6, Dennis Gruszka7, Nicole L Ward7, Johann E Gudjonsson5, J Michelle Kahlenberg8.   

Abstract

Psoriasis is a common, inflammatory autoimmune skin disease. Early detection of an IFN-1 signature occurs in many psoriasis lesions, but the source of IFN production remains debated. IFN-κ is an important source of IFN-1 production in the epidermis. We identified a correlation between IFN-regulated and psoriasis-associated genes in human lesional skin. We thus wanted to explore the effects of IFN-κ in psoriasis using the well-characterized imiquimod psoriasis model. Three mouse strains aged 10 weeks were used: wild-type C57Bl/6, C57Bl/6 that overexpress Ifnk in the epidermis (i.e., transgenic), and total body Ifnk-/- (i.e., knockout) strain. Psoriasis was induced by topical application of imiquimod on both ears for 8 consecutive days. Notably, the severity of skin lesions and inflammatory cell infiltration was more significantly increased in transgenic than in wild-type than in knockout mice. Gene expression analysis identified greater upregulation of Mxa, Il1b, Tnfa, Il6, Il12, Il23, Il17, and Ifng in transgenic compared to wild-type compared to knockout mice after imiquimod treatment. Furthermore, imiquimod increased CD8+ and CD4+ T-cell infiltration more in transgenic than in wild-type than in knockout mice. In summary, we identified IFN-κ as a rheostat for initiation of psoriasiform inflammation. This suggests that targeting IFN-1s early in the disease may be an effective way of controlling psoriatic inflammation.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34364883      PMCID: PMC8688309          DOI: 10.1016/j.jid.2021.05.029

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  44 in total

1.  Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis.

Authors:  Naresh Punwani; Peggy Scherle; Robert Flores; Jack Shi; Jinjin Liang; Swamy Yeleswaram; Richard Levy; William Williams; Alice Gottlieb
Journal:  J Am Acad Dermatol       Date:  2012-01-24       Impact factor: 11.527

Review 2.  Type I interferon in the pathogenesis of lupus.

Authors:  Mary K Crow
Journal:  J Immunol       Date:  2014-06-15       Impact factor: 5.422

3.  Misbehaving macrophages in the pathogenesis of psoriasis.

Authors:  Rachael A Clark; Thomas S Kupper
Journal:  J Clin Invest       Date:  2006-08       Impact factor: 14.808

4.  Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa.

Authors:  Johann E Gudjonsson; J Michelle Kahlenberg; Mrinal K Sarkar; Grace A Hile; Lam C Tsoi; Xianying Xing; Jianhua Liu; Yun Liang; Celine C Berthier; William R Swindell; Matthew T Patrick; Shuai Shao; Pei-Suen Tsou; Ranjitha Uppala; Maria A Beamer; Anshika Srivastava; Stephanie L Bielas; Paul W Harms; Spiro Getsios; James T Elder; John J Voorhees
Journal:  Ann Rheum Dis       Date:  2018-07-18       Impact factor: 19.103

5.  In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered.

Authors:  Leslie van der Fits; Leontine I van der Wel; Jon D Laman; Errol P Prens; Martie C M Verschuren
Journal:  J Invest Dermatol       Date:  2004-01       Impact factor: 8.551

6.  Trial of Anifrolumab in Active Systemic Lupus Erythematosus.

Authors:  Eric F Morand; Richard Furie; Yoshiya Tanaka; Ian N Bruce; Anca D Askanase; Christophe Richez; Sang-Cheol Bae; Philip Z Brohawn; Lilia Pineda; Anna Berglind; Raj Tummala
Journal:  N Engl J Med       Date:  2019-12-18       Impact factor: 91.245

7.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.

Authors:  Michael I Love; Wolfgang Huber; Simon Anders
Journal:  Genome Biol       Date:  2014       Impact factor: 13.583

8.  IL-12 protects from psoriasiform skin inflammation.

Authors:  Paulina Kulig; Stephanie Musiol; Sandra Nicole Freiberger; Bettina Schreiner; Gabor Gyülveszi; Giancarlo Russo; Stanislav Pantelyushin; Kenji Kishihara; Francesca Alessandrini; Thomas Kündig; Federica Sallusto; Günther F L Hofbauer; Stefan Haak; Burkhard Becher
Journal:  Nat Commun       Date:  2016-11-28       Impact factor: 14.919

9.  Topical imiquimod yields systemic effects due to unintended oral uptake.

Authors:  Lynda Grine; Sophie Steeland; Sara Van Ryckeghem; Marlies Ballegeer; Stefan Lienenklaus; Siegfried Weiss; Niek N Sanders; Roosmarijn E Vandenbroucke; Claude Libert
Journal:  Sci Rep       Date:  2016-01-28       Impact factor: 4.379

Review 10.  Cytokinocytes: the diverse contribution of keratinocytes to immune responses in skin.

Authors:  Yanyun Jiang; Lam C Tsoi; Allison C Billi; Nicole L Ward; Paul W Harms; Chang Zeng; Emanual Maverakis; J Michelle Kahlenberg; Johann E Gudjonsson
Journal:  JCI Insight       Date:  2020-10-15
View more
  1 in total

1.  IFN-κ is critical for normal wound repair and is decreased in diabetic wounds.

Authors:  Sonya J Wolf; Christopher O Audu; Amrita Joshi; Aaron denDekker; William J Melvin; Frank M Davis; Xianying Xing; Rachael Wasikowski; Lam C Tsoi; Steven L Kunkel; Johann E Gudjonsson; Mary X O'Riordan; J Michelle Kahlenberg; Katherine A Gallagher
Journal:  JCI Insight       Date:  2022-05-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.